Top Markets
Coin of the day
Egetis Therapeutics AB (publ) Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ)

EGTX
Peringkat dalam Saham #14551
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to... Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
Harga Saham
$0.87679425
Terakhir disinkronkan: 2026-08-31
Kapitalisasi Pasar
$407.66M
Perubahan (1 hari)
-1.88%
Perubahan (1 tahun)
58.03%
Negara
SE
Perdagangan Egetis Therapeutics AB (publ) (EGTX)

Kategori

Rasio P/S untuk Egetis Therapeutics AB (publ) (EGTX)
Rasio P/S per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Egetis Therapeutics AB (publ), rasio P/S saat ini (TTM) adalah 0. Pada akhir 2026, rasio P/S perusahaan adalah 0.
Riwayat rasio P/S untuk Egetis Therapeutics AB (publ) dari 2026 hingga 2026
Rasio P/S pada akhir setiap tahun
Tahun Rasio P/S Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/S untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/S Perbedaan Rasio P/S Negara
10.95 -
US
12.19 -
NL
3.75 -
AU
24.99 -
US
- -
CH